Skip to content
Bending the Curve Trial by Trial
?

Back to Chronic myeloid leukemia

References: Chronic myeloid leukemia

125 sources cited on this page. Links open the primary source.

  1. Craigie D (case 1), Bennett JH (case 2). Two cases of disease and enlargement of the spleen, in which death took place from the presence of purulent matter in the blood. Edinb Med Surg J. 1845;64(165):400-423. PubMed
    CiteLoading…
  2. GALTON DA. Myleran in chronic myeloid leukaemia; results of treatment. Lancet. 1953;264(6753):208-13. PubMedDOI
    CiteLoading…
  3. HADDOW A, TIMMIS GM. Myleran in chronic myeloid leukaemia; chemical constitution and biological action. Lancet. 1953;264(6753):207-8. PubMedDOI
    CiteLoading…
  4. SCHILLING RF, MEYER OO. Treatment of chronic granulocytic leukemia with 1, 4-dimethanesulfonyloxybutane (myleran). N Engl J Med. 1956;254(21):986-9. PubMedDOI
    CiteLoading…
  5. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25:85-109. PubMedDOI
    CiteLoading…
  6. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia (abstract). Science. 1960;132:1497.
    CiteLoading…
  7. BRIDGES JM, HAYES DM, NELSON MG. Busulphan in the treatment of chronic granulocytic leukaemia. Br J Cancer. 1961;15(3):468-78. PubMedDOI
    CiteLoading…
  8. Nowell PC, Hungerford DA. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J Natl Cancer Inst. 1961;27:1013-35. PubMedDOI
    CiteLoading…
  9. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290-3. PubMedDOI
    CiteLoading…
  10. Fefer A, Cheever MA, Thomas ED, Boyd C, Ramberg R, Glucksberg H, et al. Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N Engl J Med. 1979;300(7):333-7. PubMedDOI
    CiteLoading…
  11. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1982;300(5894):765-7. PubMedDOI
    CiteLoading…
  12. Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, et al. Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature. 1983;306(5940):239-42. PubMedDOI
    CiteLoading…
  13. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood. 1983;62(3):689-92. PubMed
    CiteLoading…
  14. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36(1):93-9. PubMedDOI
    CiteLoading…
  15. Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell. 1984;37(3):1035-42. PubMedDOI
    CiteLoading…
  16. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63(4):789-99. PubMed
    CiteLoading…
  17. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph' translocation. Nature. 1985;315(6022):758-61. PubMedDOI
    CiteLoading…
  18. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315(6020):550-4. PubMedDOI
    CiteLoading…
  19. Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AW, Batchelor R, et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med. 1986;314(4):202-7. PubMedDOI
    CiteLoading…
  20. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med. 1986;314(17):1065-9. PubMedDOI
    CiteLoading…
  21. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247(4944):824-30. PubMedDOI
    CiteLoading…
  22. Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76(12):2462-5. PubMed
    CiteLoading…
  23. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood. 1993;82(2):398-407. PubMed
    CiteLoading…
  24. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994;84(12):4064-77. PubMed
    CiteLoading…
  25. Italian Cooperative Study Group on Chronic Myeloid Leukemia, Tura S, Baccarani M, Zuffa E, Russo D, Fanin R, et al. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330(12):820-5. PubMedDOI
    CiteLoading…
  26. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86(5):2041-50. PubMed
    CiteLoading…
  27. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561-6. PubMedDOI
    CiteLoading…
  28. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997;337(4):223-9. PubMedDOI
    CiteLoading…
  29. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90(11):850-8. PubMedDOI
    CiteLoading…
  30. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. Blood. 1998;92(5):1541-8. PubMed
    CiteLoading…
  31. Degos L. John Hughes Bennett, Rudolph Virchow... and Alfred Donné: the first description of leukemia. Hematol J. 2001;2(1):1. PubMed
    CiteLoading…
  32. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-1037. PubMedDOI
    CiteLoading…
  33. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344(14):1038-42. PubMedDOI
    CiteLoading…
  34. European Medicines Agency. Glivec (imatinib): European public assessment report (EPAR) page. Marketing authorisation issued 07/11/2001; page last updated 12/11/2025. Page read 2026-10-20. Source
  35. US Food and Drug Administration. Approval letter, Gleevec (imatinib mesylate) capsules, NDA 21-335, Novartis Pharmaceuticals Corporation. Approval date 10 May 2001 (the letter's own date line is in an unextracted signature page; the later NDA 21-335/S-004 letter refers to the approval letter of May 10, 2001). Source
  36. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531):876-80. PubMedDOI
    CiteLoading…
  37. US Food and Drug Administration. Approval letter, Gleevec (imatinib mesylate) 100 mg capsules, NDA 21-335/S-004, Novartis Pharmaceuticals Corporation; electronic signature dated 12/20/02 (scanned document read as images). Source
  38. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346(9):645-52. PubMedDOI
    CiteLoading…
  39. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349(15):1423-32. PubMedDOI
    CiteLoading…
  40. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004. PubMedDOI
    CiteLoading…
  41. European Medicines Agency (EMEA). Glivec: scientific discussion (initial scientific discussion for the approval of Glivec, updated until 1 September 2004), EPAR. Read 2026-10-20. Source
  42. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809-20. PubMedDOI
    CiteLoading…
  43. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-17. PubMedDOI
    CiteLoading…
  44. European Medicines Agency. Sprycel (dasatinib): European public assessment report (EPAR) page. Marketing authorisation issued 20/11/2006; page last updated 02/10/2026. Page read 2026-10-20. Source
  45. European Medicines Agency (EMEA). Sprycel: scientific discussion (2006), EPAR. Read 2026-10-20. Source
  46. US Food and Drug Administration. Approval letter, Sprycel (dasatinib) tablets, NDA 21-986, Bristol-Myers Squibb Company; electronic signature dated 6/28/2006. Source
  47. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2006;91(4):513-21. PubMed
    CiteLoading…
  48. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37. PubMedDOI
    CiteLoading…
  49. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542-51. PubMedDOI
    CiteLoading…
  50. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531-41. PubMedDOI
    CiteLoading…
  51. European Medicines Agency. Tasigna (nilotinib): EPAR product page, marketing authorisation issued 19/11/2007. Page text on stopping treatment read 20 October 2026; date of that wording not stated. Source
  52. European Medicines Agency (EMEA). Tasigna: scientific discussion (2007), EPAR. Read 2026-10-20. Source
  53. US Food and Drug Administration. Approval letter, Tasigna (nilotinib) capsules, NDA 22-068, Novartis Pharmaceuticals Corporation; electronic signature dated 10/29/2007. Source
  54. Nowell PC. Discovery of the Philadelphia chromosome: a personal perspective. J Clin Invest. 2007;117(8):2033-5. PubMedDOI
    CiteLoading…
  55. US Food and Drug Administration. Approval letter, Sprycel (dasatinib) tablets, NDA 21-986/S-004, Bristol-Myers Squibb Company; electronic signature dated 5/21/2009. Source
  56. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401-12. PubMedDOI
    CiteLoading…
  57. US Food and Drug Administration. Accelerated approval letter, Sprycel (dasatinib) tablets, NDA 021986/S-008 (newly diagnosed adults with CML in chronic phase), Bristol Myers Squibb; signed 10/28/2010. Source
  58. US Food and Drug Administration. Supplement approval letter, Tasigna (nilotinib) capsules, NDA 022068/S-004 and S-005 (S-005 accelerated approval for newly diagnosed Ph+ CML in chronic phase), Novartis Pharmaceuticals Corporation; signed 06/17/2010. Source
  59. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-70. PubMedDOI
    CiteLoading…
  60. Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-35. PubMedDOI
    CiteLoading…
  61. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251-9. PubMedDOI
    CiteLoading…
  62. Cortes JE, Kim DW, Kantarjian HM, Brümmendorf TH, Dyagil I, Griskevicius L, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30(28):3486-92. PubMedDOI
    CiteLoading…
  63. US Food and Drug Administration. NDA approval letter, Bosulif (bosutinib) tablets, NDA 203341, Wyeth Pharmaceuticals, Inc.; signed 09/04/2012. Source
  64. US Food and Drug Administration. Accelerated approval letter, Iclusig (ponatinib) tablets, NDA 203469, ARIAD Pharmaceuticals Inc.; signed 12/14/2012. Source
  65. Kampen KR. The discovery and early understanding of leukemia. Leuk Res. 2012;36(1):6-13. PubMedDOI
    CiteLoading…
  66. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-84. PubMedDOI
    CiteLoading…
  67. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783-96. PubMedDOI
    CiteLoading…
  68. European Medicines Agency. Bosulif (bosutinib): European public assessment report (EPAR) page. Conditional marketing authorisation 27 March 2013, switched to full marketing authorisation 7 April 2022 (as stated on the page); page last updated 12/01/2026. Page read 2026-10-20. Source
  69. European Medicines Agency. Iclusig: assessment report EMA/CHMP/220290/2013 (initial marketing authorisation application, accelerated assessment). Read 2026-10-20. Source
  70. European Medicines Agency. Iclusig (ponatinib): European public assessment report (EPAR) page. Marketing authorisation issued 01/07/2013; page last updated 31/07/2026. Page read 2026-10-20. Source
  71. US Food and Drug Administration. Supplement approval and REMS approval letter, Iclusig (ponatinib) tablets, NDA 203469/S-007 and S-008, ARIAD Pharmaceuticals; signed 12/20/2013. Source
  72. Druker BJ. Janet Rowley (1925-2013). Nature. 2014;505(7484):484. PubMedDOI
    CiteLoading…
  73. Brümmendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvillié L, Pavlov D, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015;168(1):69-81. PubMedDOI
    CiteLoading…
  74. Sasaki K, Strom SS, O'Brien S, Jabbour E, Ravandi F, Konopleva M, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2(5):e186-93. PubMedDOI
    CiteLoading…
  75. Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol. 2016;34(24):2851-7. PubMedDOI
    CiteLoading…
  76. Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016;34(20):2333-40. PubMedDOI
    CiteLoading…
  77. Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044-54. PubMedDOI
    CiteLoading…
  78. Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48-56. PubMedDOI
    CiteLoading…
  79. Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G, et al. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol. 2017;4(7):e310-e316. PubMedDOI
    CiteLoading…
  80. Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, et al. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. J Clin Oncol. 2017;35(3):298-305. PubMedDOI
    CiteLoading…
  81. US Food and Drug Administration. Accelerated approval letter, Bosulif (bosutinib) tablets, NDA 203341/S-009 (newly diagnosed chronic phase Ph+ CML), PF Prism C.V. c/o Pfizer Inc.; signed 12/19/2017. Source
  82. US Food and Drug Administration. Supplement approval letter, NDA 022068/S-026, Tasigna (nilotinib) capsules, signed 22 December 2017. Source
  83. Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv41-iv51. PubMedDOI
  84. Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gómez Casares MT, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31(7):1525-1531. PubMedDOI
    CiteLoading…
  85. Hochhaus A, Larson RA, Guilhot F, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017;376(10):917-927. PubMedDOI
    CiteLoading…
  86. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132(4):393-404. PubMedDOI
    CiteLoading…
  87. Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol. 2018;36(3):231-237. PubMedDOI
    CiteLoading…
  88. Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747-757. PubMedDOI
    CiteLoading…
  89. Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019;381(24):2315-2326. PubMedDOI
    CiteLoading…
  90. US Food and Drug Administration. Supplement approval letter, Iclusig (ponatinib) tablets, NDA 203469/S-034, ARIAD Pharmaceuticals, Inc.; signed 12/18/2020. Source
  91. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-984. PubMedDOI
    CiteLoading…
  92. Pfirrmann M, Clark RE, Prejzner W, Lauseker M, Baccarani M, Saussele S, et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020;34(8):2138-2149. PubMedDOI
    CiteLoading…
  93. Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138(21):2042-2050. PubMedDOI
    CiteLoading…
  94. US Food and Drug Administration. Supplement approval and fulfilment of postmarketing requirement letter, Bosulif (bosutinib) tablets, NDA 203341/S-020, PF Prism C.V. c/o Pfizer Inc.; signed 05/14/2021. Source
  95. US Food and Drug Administration. Accelerated approval letter, NDA 215358/Original 1, SCEMBLIX (asciminib) tablets, signed 29 October 2021. Source
  96. US Food and Drug Administration. NDA approval letter, NDA 215358/Original 2, SCEMBLIX (asciminib) tablets (Ph+ CML in chronic phase with the T315I mutation), signed 29 October 2021. Source
  97. Hughes TP, Clementino NCD, Fominykh M, Lipton JH, Turkina AG, Moiraghi EB, et al. Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update. Leukemia. 2021;35(6):1631-1642. PubMedDOI
    CiteLoading…
  98. Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440-453. PubMedDOI
    CiteLoading…
  99. Minciacchi VR, Kumar R, Krause DS. Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future. Cells. 2021;10(1). PubMedDOI
    CiteLoading…
  100. Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138(21):2031-2041. PubMedDOI
    CiteLoading…
  101. European Medicines Agency, CHMP. Scemblix (asciminib): summary of opinion (initial authorisation), EMA/CHMP/587767/2022, 23 June 2022. Source
  102. European Medicines Agency. Scemblix (asciminib): EPAR product page (EMEA/H/C/005605), authorisation 25/08/2022. Source
  103. US Food and Drug Administration. Supplement approval and fulfilment of postmarketing requirement letter, Iclusig (ponatinib) tablets, NDA 203469/S-035 (labeling update from the final OPTIC study report), Takeda Pharmaceuticals U.S.A., Inc.; signed 02/15/2022. Source
  104. US Food and Drug Administration. Supplement approval and fulfilment of postmarketing requirement letter, NDA 215358/S-001, SCEMBLIX (asciminib), signed 12 October 2022. Source
  105. Radich JP. Another Philadelphia story. Haematologica. 2022;107(3):566-567. PubMedDOI
    CiteLoading…
  106. Hochhaus A, Réa D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37(3):617-626. PubMedDOI
    CiteLoading…
  107. Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson SM, Saussele S, Rea D, et al. Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE. Br J Haematol. 2023;202(5):942-952. PubMedDOI
    CiteLoading…
  108. US Food and Drug Administration. FDA grants accelerated approval to asciminib for newly diagnosed chronic myeloid leukemia. Page dated 29 October 2024. Source
  109. US Food and Drug Administration. Accelerated approval letter, NDA 215358/S-008, Scemblix (asciminib) tablets, signed 29 October 2024. Source
  110. US Food and Drug Administration. Supplement approval letter, NDA 215358/S-009, Scemblix (asciminib) tablets, signed 29 October 2024. Source
  111. Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, et al. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med. 2024;391(10):885-898. PubMedDOI
    CiteLoading…
  112. Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, et al. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(1):43-69. PubMedDOI
  113. Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39(8):1797-1813. PubMedDOI
    CiteLoading…
  114. Novartis. Novartis Scemblix receives positive CHMP opinion for treatment of adults with newly diagnosed CML. Press release, Basel, 17 October 2025. Source
  115. Cortes JE, Hughes TP, Wang J, Kim DW, Kim DDH, Mayer J, et al. Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial. Blood. 2026;147(13):1433-1446. PubMedDOI
    CiteLoading…
  116. Cancer Research UK. Chronic myeloid leukaemia (CML) survival statistics. Health professional page. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-cml/survival. Page accessed 20 October 2026. Source
  117. ClinicalTrials.gov. NCT03459534 (Radotinib after TKI failure or intolerance). Registry record, accessed 20 October 2026. NCT03459534
  118. ClinicalTrials.gov. NCT05753384 (Poitiers TKI discontinuation study). Registry record, accessed 20 October 2026. NCT05753384
  119. ClinicalTrials.gov. NCT06423911 (POLARIS-2). Registry record, accessed 20 October 2026. NCT06423911
  120. ClinicalTrials.gov. NCT07489755 (TGRX-678). Registry record, accessed 20 October 2026. NCT07489755
  121. DailyMed. SCEMBLIX (asciminib) tablet, film coated, Novartis Pharmaceuticals Corporation; SPL version 13, published 29 September 2026. Source
  122. European Commission. Union Register of medicinal products: Scemblix (EU/1/22/1670), list of Commission decisions and procedures (page dated 31/07/2026). Source
  123. Kantarjian H, Deininger M, Apperley JF, Arthur CK, Chuah C, Hochhaus A, et al. Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial. Leukemia. 2026;40(9):1882-1892. PubMedDOI
    CiteLoading…
  124. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts: Chronic Myeloid Leukemia (CML). Page accessed 20 October 2026; no update date is displayed on the page (its HTML last_modified metadata reads 22 April 2026). Source
  125. Tungjitviboonkun S, Daran L, Unsuwan S. Chronic Myeloid Leukemia: Historical Perspective, Pathophysiology, and Treatment Advances. Acta Haematol. 2026;:1-16. PubMedDOI
    CiteLoading…